Pronóstico del mercado de la epilepsia en América del Norte hasta 2030: análisis regional, por tipo (epilepsia mioclónica progresiva, epilepsia refleja, epilepsia generalizada y otras), vía de administración (oral, parenteral y otras), tipo de tratamiento (medicamentos de primera generación, medicamentos de segunda generación y medicamentos de tercera generación), grupo de edad (adultos y niños) y canal de distribución (farmacias hospitalarias, farmacias minoristas y otras)
La creciente prevalencia de la epilepsia impulsa el mercado de la epilepsia en América del Norte
La epilepsia, también denominada trastorno convulsivo, es una enfermedad crónica del cerebro. Se caracteriza por convulsiones recurrentes, que son breves episodios de movimiento involuntario de una parte del cuerpo o de todo el cuerpo. Las convulsiones pueden alterar las sensaciones, los comportamientos, la conciencia y los movimientos musculares. La epilepsia puede producirse debido a un trastorno genético o una lesión cerebral adquirida, como un traumatismo o un accidente cerebrovascular. Según los datos publicados por la Organización Mundial de la Salud (OMS) en febrero de 2023, la epilepsia representa una parte importante de la carga mundial de morbilidad y afecta a casi 50 millones de personas en todo el mundo. Además, se estima que entre 4 y 10 personas por cada 1.000 habitantes padecen epilepsia activa (es decir, que necesitan tratamiento o sufren convulsiones continuas). Casi 5 millones de personas son diagnosticadas con epilepsia cada año. Se estima que los países de altos ingresos notifican casos de epilepsia a una tasa de 49 por cada 100.000 personas al año. Esta cifra puede llegar a 139 por cada 100.000 personas en los países de ingresos bajos y medios. El aumento de la incidencia de la epilepsia puede atribuirse al mayor número de lesiones por accidentes de tráfico y lesiones relacionadas con el nacimiento, y al riesgo elevado de enfermedades endémicas como la neurocisticercosis o la malaria. La OMS también afirma que aproximadamente el 70% de las personas con epilepsia pueden dejar de tener convulsiones con el uso de medicamentos. Los tratamientos para controlar la epilepsia incluyen medicamentos antiepilépticos, dietas especiales (además de medicamentos anticonvulsivos) y cirugía; sin embargo, la terapia con medicamentos antiepilépticos es el tratamiento principal que se prescribe a la mayoría de los pacientes. Por lo tanto, la creciente prevalencia de la epilepsia en todo el mundo impulsa el crecimiento del mercado.
Descripción general del mercado de la epilepsia en América del Norte
El mercado de la epilepsia en América del Norte está segmentado en Estados Unidos, Canadá y México. El crecimiento del mercado en esta región se atribuye al aumento del número de personas afectadas por epilepsia, el creciente envejecimiento de la población, la I+D en curso en el campo de los medicamentos para la epilepsia en la región, las crecientes aprobaciones regulatorias para nuevos productos y el aumento del número de accidentes y lesiones cerebrales en los medicamentos para la epilepsia.
Ingresos y pronóstico del mercado de la epilepsia en América del Norte hasta 2030 (millones de USD)
Segmentación del mercado de la epilepsia en América del Norte
El mercado de la epilepsia en América del Norte se clasifica en tipo, vía de administración, tipo de tratamiento, grupo de edad, canal de distribución y país.
Según el tipo, el mercado de la epilepsia en América del Norte se clasifica en epilepsia mioclónica progresiva, epilepsia refleja, epilepsia generalizada y otras. El segmento de epilepsia generalizada tuvo la mayor participación de mercado en 2022.
En términos de vía de administración, el mercado de la epilepsia en América del Norte se clasifica en oral, parenteral y otros. El segmento oral tuvo la mayor participación de mercado en 2022.
Por tipo de tratamiento, el mercado de la epilepsia en América del Norte se segmenta en medicamentos de primera generación, medicamentos de segunda generación y medicamentos de tercera generación. El segmento de medicamentos de tercera generación tuvo la mayor participación de mercado en 2022.
Según el grupo de edad, el mercado de la epilepsia en América del Norte se bifurca en adultos y niños. El segmento de adultos tuvo una mayor participación de mercado en 2022.
En términos de canal de distribución, el mercado de la epilepsia en América del Norte se clasifica en farmacias hospitalarias, farmacias minoristas y otros. El segmento de farmacias hospitalarias tuvo la mayor participación de mercado en 2022.
Por país, el mercado de la epilepsia en América del Norte está segmentado en EE. UU., Canadá y México. Estados Unidos dominó la participación en el mercado de la epilepsia en América del Norte en 2022.
Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc y H. Lundbeck AS son algunas de las empresas líderes que operan en el mercado de la epilepsia en América del Norte.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation - Overview
4.1.3.1.2 Gene Modulation - Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
4.1.3.1.4 Neuropeptides - Overview
4.1.3.1.5 Engineered Channels - Overview
4.1.3.1.6 Endogenous Channels - Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels for Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. North America Epilepsy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market - North America Analysis
6.1 North America: Epilepsy Market Overview
7. North America Epilepsy Market Analysis - by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Epilepsy Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9. North America Epilepsy Market Analysis - by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10. North America Epilepsy Market Analysis - by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11. North America Epilepsy Market Analysis - by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12. North America Epilepsy Market - Country Analysis
12.1 North America Epilepsy Market Overview
12.1.1 North America: Epilepsy Market Breakdown- by Country, 2022 and 2030 (%)
12.1.1.1.1 United States: Epilepsy Market Overview
12.1.1.1.2 United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.1.3 United States: Epilepsy Market Breakdown, by Type
12.1.1.1.4 United States: Epilepsy Market Breakdown, by Route of Administration
12.1.1.1.5 United States: Epilepsy Market Breakdown, by Treatment Type
12.1.1.1.6 United States: Epilepsy Market Breakdown, by Age Group
12.1.1.1.7 United States: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.1.8 Canada: Epilepsy Market Overview
12.1.1.1.9 Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.1.10 Canada: Epilepsy Market Breakdown, by Type
12.1.1.1.11 Canada: Epilepsy Market Breakdown, by Route of Administration
12.1.1.1.12 Canada: Epilepsy Market Breakdown, by Treatment Type
12.1.1.1.13 Canada: Epilepsy Market Breakdown, by Age Group
12.1.1.1.14 Canada: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.1.15 Mexico: Epilepsy Market Overview
12.1.1.2 Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 Mexico: Epilepsy Market Breakdown, by Type
12.1.1.2.2 Mexico: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 Mexico: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 Mexico: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 Mexico: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 LivaNova Plc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Novartis AG
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Medtronic Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 GSK Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 H. Lundbeck AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. Appendix
15.1 About The Insight Partners
List of Tables
Table 1. North America Epilepsy Market Segmentation
Table 2. Cell Therapy Approach - An Overview
Table 3. Gene Therapy Approach - An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Target Types Overview
Table 11. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 12. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 13. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type
Table 14. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group
Table 15. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 16. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 17. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 18. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type
Table 19. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group
Table 20. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 21. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 22. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 23. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type
Table 24. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group
Table 25. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 26. Recent Organic Growth Strategies in Epilepsy Market
Table 27. Recent Inorganic Growth Strategies in the Epilepsy Market
?
List of Figures
Figure 1. North America Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. North America: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. North America: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 30. Growth Strategies in Epilepsy Market
?
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- LivaNova Plc
- Novartis AG
- Medtronic Plc
- GSK Plc
- H. Lundbeck AS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America epilepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America epilepsy market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.